Acute Myeloid Leukemia Clinical Trials in Boston, Massachusetts

32 studies are recruiting for acute myeloid leukemia in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. Revumenib in Combination With 7+3 + Midostaurin in AML

   This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaur…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Richard Stone, MD

   See if you can join NCT06313437 on ClinicalTrials.gov

2. Ziftomenib Maintenance Post Allo-HCT

   The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT06440135 on ClinicalTrials.gov

3. A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

   Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in pat…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   44 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT05735184 on ClinicalTrials.gov

4. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

   This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   DFCI/BWH Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06059391 on ClinicalTrials.gov

5. A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

   This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   DFCI, Boston, Massachusetts

   Locations

   7 in total

   Run by

   Solu Therapeutics, Inc

   See if you can join NCT06950034 on ClinicalTrials.gov

6. BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

   The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The names of the study drugs involved in this study are/is: * BXCL701

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Run by

   Eric Stephen Winer, MD

   See if you can join NCT05703542 on ClinicalTrials.gov

7. Study of REM-422 in Patients With AML or Higher Risk MDS

   The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   9 in total

   Run by

   Remix Therapeutics

   See if you can join NCT06297941 on ClinicalTrials.gov